Side-by-side · Research reference

AHK-CuvsHGH 191AA

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED14/43 cited

BFDA-ApprovedHUMAN-REVIEWED0/75 cited

AHK-Cu

Tripeptide-Copper Complex · Cosmetic

10⁻¹² – 10⁻⁹ MActive range (in vitro)Pyo 2007

Dermal papilla cellsPrimary targetPyo 2007

TopicalRoute

Topical · Scalp / Skin

HGH 191AA

Recombinant hGH · FDA-Approved

0.024–0.034 mg/kg/dayPediatric GHD dose

2–4 hoursPlasma half-life

191 AASequence length

SQ · Daily · Evening preferred

01Mechanism of Action

Parameter

AHK-Cu

HGH 191AA

Primary target

Dermal papilla cells (DPCs) — specialized fibroblasts in hair follicle morphogenesisPyo 2007

Growth hormone receptor (GHR) — JAK2/STAT5 pathway

Pathway

AHK-Cu → DPC proliferation → VEGF elevation, TGF-β1 suppression → Angiogenesis, follicle elongationPyo 2007

GHR activation → JAK2/STAT5 → liver IGF-1 synthesis + direct metabolic effects

Downstream effect

Stimulates hair follicle elongation ex vivo, reduces dermal papilla cell apoptosis, elevates Bcl-2/Bax ratio, reduces cleaved caspase-3 and PARPPyo 2007

Linear growth, lipolysis, protein synthesis, nitrogen retention, carbohydrate metabolism modulation

Feedback intact?

—

No — exogenous GH bypasses hypothalamic-pituitary axis, suppresses endogenous pulsatility

Origin

Synthetic tripeptide with Cu²⁺ chelation — alanine substitution variant of GHK-Cu

Recombinant DNA technology — 191 AA, identical to pituitary hGH, no methionyl residue

Antibody development

—

Rare — <2% develop binding antibodies, typically non-neutralizing

02Dosage Protocols

Parameter

AHK-Cu

HGH 191AA

Effective concentration (in vitro)

10⁻¹² – 10⁻⁹ MPyo 2007

Stimulated human hair follicle elongation ex vivo and DPC proliferation in vitro.

—

Topical formulation

0.001–0.01% (estimated cosmetic range)

No standardized human protocol published — extrapolated from in vitro data.

—

Frequency

Once or twice daily (topical application)

Once daily, typically evening

Evening administration mimics physiological GH pulse.

Route

Topical — scalp or dermal application

—

Evidence basis

Ex vivo hair follicle / in vitro DPC studiesPyo 2007

FDA-approved / decades of RCT data

Duration

Not established — cosmetic protocols typically 8–12 weeks

Years (children until epiphyseal closure); indefinite (adult GHD)

Pediatric GHD

—

0.024–0.034 mg/kg/day SQ

6–7× per week dosing typical. Brand-specific ranges.

Adult GHD

—

0.004–0.016 mg/kg/day SQ

Start low, titrate based on IGF-1 levels.

Turner syndrome

—

0.045–0.050 mg/kg/day SQ

Idiopathic short stature

—

0.037 mg/kg/day SQ

AIDS wasting

—

0.1 mg/kg/day SQ (high-dose)

Short-term indication. Monitor glucose.

Monitoring

—

IGF-1, glucose, thyroid function, bone age (children)

03Metabolic / Fat Loss Evidence

Parameter

AHK-Cu

HGH 191AA

Primary fat target

—

Visceral and subcutaneous adipose tissue

Mechanism

—

Lipolysis via hormone-sensitive lipase activation, FFA oxidation

Effect on lean mass

—

Significant lean mass increase (protein synthesis, nitrogen retention)

Insulin sensitivity

—

Acute insulin resistance (anti-insulin effect); chronic neutral-to-improved via fat loss

IGF-1 elevation

—

Dose-dependent, significant — primary anabolic mediator

Glucose metabolism

—

Hyperglycemia risk, especially high doses (AIDS wasting)

Body composition

—

↓ fat mass, ↑ lean mass, ↑ bone mineral density (children)

Clinical context

—

FDA-approved for AIDS wasting (cachexia). Off-label use for body recomposition lacks long-term safety data.

04Side Effects & Safety

Parameter

AHK-Cu

HGH 191AA

Local irritation

Mild erythema, pruritus at application site (copper peptide class effect)

—

Copper sensitivity

Rare hypersensitivity reaction in copper-sensitive individuals

—

Systemic absorption

Minimal via topical route — systemic copper toxicity unlikely at cosmetic doses

—

Data limitations

No published human safety trials — cosmetic use presumed safe per class precedent (GHK-Cu)

—

Injection site reaction

—

Lipohypertrophy, lipoatrophy, erythema (rotate sites)

Fluid retention / Edema

—

Peripheral edema, arthralgia, carpal tunnel syndrome (dose-dependent)

Glucose intolerance

—

Hyperglycemia, new-onset diabetes (anti-insulin effect)

Intracranial hypertension

—

Benign intracranial hypertension (pseudotumor cerebri) — headache, visual changes, papilledema

Slipped capital femoral epiphysis

—

SCFE risk in children — limp, hip/knee pain (requires surgery)

Scoliosis progression

—

Rapid growth may unmask/progress scoliosis (monitor spine in children)

Hypothyroidism

—

Central hypothyroidism unmasking or worsening (monitor TSH, free T4)

Cancer risk

—

Contraindicated in active malignancy. Theoretical risk in cancer survivors (controversial).

Antibody formation

—

Rare (<2%), typically non-neutralizing. Loss of efficacy if neutralizing antibodies develop.

Pancreatitis

—

Rare. Higher risk in children with certain syndromes (Prader-Willi).

Gynecomastia

—

Adolescent males (physiological during puberty, may be exacerbated)

Absolute Contraindications

AHK-Cu

·Known copper allergy or Wilson's disease

HGH 191AA

·Active malignancy or history of cancer (especially childhood cancer survivors with risk factors)
·Acute critical illness (post-cardiac surgery, trauma, acute respiratory failure)
·Diabetic retinopathy (active proliferative or severe non-proliferative)
·Prader-Willi syndrome with severe obesity, sleep apnea, or respiratory impairment
·Closed epiphyses (for growth indications)

Relative Contraindications

AHK-Cu

·Broken or inflamed skin (increased absorption risk)
·Concurrent use of other copper-containing formulations

HGH 191AA

·Diabetes mellitus (monitor closely, may require insulin adjustment)
·Intracranial lesions or history of intracranial hypertension
·Scoliosis (monitor curve progression)
·Untreated hypothyroidism (treat before GH initiation)
·Severe obesity (assess OSA risk, cardiovascular status)

05Administration Protocol

Parameter

AHK-Cu

HGH 191AA

1. Topical application

Apply to clean, dry scalp or target dermal area. Typical cosmetic formulations: 0.001–0.01% AHK-Cu in serum or cream base.

Add diluent (sterile water or bacteriostatic water per manufacturer) to vial. Swirl gently — do not shake. Solution should be clear, colorless. Concentration varies by brand (e.g., 5 mg or 10 mg per vial).

2. Frequency

Once or twice daily. Evening application preferred for overnight contact time.

Subcutaneous — rotate sites: abdomen, thigh, buttocks, upper arm. Avoid same site within 1 cm for 2 weeks to prevent lipodystrophy.

3. Scalp preparation

For hair growth: apply directly to scalp, massage gently. No need to rinse. Allow absorption for minimum 2–4 hours.

Once daily, evening preferred (6–8 PM or pre-sleep). Mimics physiological nocturnal GH secretion. Consistency is critical.

4. Storage

Room temperature, protected from light. Copper complexes may degrade in UV exposure.

Unreconstituted: refrigerate 2–8 °C, protect from light. Reconstituted: refrigerate, use within 14–28 days (brand-specific). Do not freeze.

5. Duration

Minimum 8–12 weeks to assess efficacy in hair growth applications, per typical cosmetic peptide protocols.

27–31G, 4–8 mm insulin syringe or pen device. Pinch skin, 45–90° angle depending on subcutaneous thickness.

6. Monitoring

—

Baseline and periodic: IGF-1 (target age/sex-adjusted midrange), fasting glucose, HbA1c, thyroid function (TSH, free T4), bone age (children), lipid panel. Fundoscopy if headache/visual symptoms.

06Stack Synergy

AHK-Cu

+ GHK-Cu

Moderate

View GHK-Cu →

Both tripeptide-copper complexes share overlapping angiogenic and wound-healing mechanisms (VEGF elevation, TGF-β modulation, fibroblast proliferation). AHK-Cu's alanine substitution may offer distinct receptor affinity or pharmacokinetics. Co-formulation could provide complementary dermal signaling, though no direct synergy studies exist. Often used interchangeably or in alternating protocols.

AHK-Cu: 0.001–0.01% topical · AM
GHK-Cu: 0.001–0.01% topical · PM
Frequency: Daily alternation or combined formulation
Primary benefit: Comprehensive dermal regeneration, angiogenesis, hair follicle support

HGH 191AA

+ Ipamorelin

Moderate

View Ipamorelin →

Ipamorelin (GHRP) stimulates endogenous GH release, which is redundant when exogenous rhGH is administered. However, ipamorelin may still amplify pulsatility of remaining endogenous secretion in partial GHD or during GH dose titration. Not typically combined in standard clinical practice; more common in experimental or off-label protocols. Limited evidence for additive benefit.

HGH 191AA: Standard dose per indication
Ipamorelin: 100–200 mcg SQ · morning (if used)
Note: Monitor IGF-1 closely; avoid supraphysiological levels
Primary benefit: Theoretical enhancement of pulsatility; limited clinical rationale

+ Tesamorelin

Weak

View Tesamorelin →

Tesamorelin (GHRH analogue) stimulates endogenous GH secretion, which is unnecessary when exogenous rhGH is already provided. Combining both offers no mechanistic advantage and increases cost, side effects, and IGF-1 elevation risk. Not recommended in clinical practice.

Note: Combination not recommended — choose one GH modality
Primary benefit: None — redundant mechanisms